Neuronetics_logo-RGB purple.png
NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols
February 23, 2021 08:00 ET | Neuronetics
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics to Report Fourth Quarter and Fiscal Year 2020 Financial and Operating Results and Host Conference Call
February 16, 2021 07:00 ET | Neuronetics
MALVERN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Announces Strategic Leadership Promotions to Support Future Growth
February 11, 2021 08:00 ET | Neuronetics
MALVERN, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 10, 2021 07:00 ET | Neuronetics
MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...
Neuronetics_logo-RGB purple.png
Neuronetics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
February 02, 2021 16:05 ET | Neuronetics
MALVERN, Pa., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing...
NEURONETICS_logo high res.jpg
Neuronetics Announces Pricing of $75 Million Public Offering of Common Stock
January 28, 2021 22:30 ET | Neuronetics
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing...
NEURONETICS_logo high res.jpg
Neuronetics Announces Proposed Public Offering of Common Stock
January 28, 2021 16:01 ET | Neuronetics
MALVERN, Pa., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a commercial stage medical technology company focused on designing, developing and marketing...
NEURONETICS_logo high res.jpg
NeuroStar® Advanced Therapy’s Depression Outcomes Registry Hits 10,000 Patient Milestone
January 19, 2021 08:00 ET | Neuronetics
MALVERN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...
NEURONETICS_logo high res.jpg
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results
January 12, 2021 16:05 ET | Neuronetics
MALVERN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...
NEURONETICS_logo high res.jpg
Neuronetics to Participate at the 23rd Annual ICR Westwicke Conference
January 07, 2021 16:30 ET | Neuronetics
MALVERN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve...